IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) plus nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Veronique Dieras; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens

Conference Proceedings

IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) plus nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Veronique Dieras, Volkmar Henschel, Luciana Molinero, Stephen Y Chui, Amreen Husain, Eric P Winer, Sherene Loi, Leisha A Emens

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019

DOI: 10.1200/JCO.2019.37.15_suppl.1003

IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) plus nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

University of Melbourne Researchers

Citation metrics

Keywords

STUDY AT MELBOURNE

ABOUT US

CONTACT & MAPS

ALUMNI & FRIENDS

RESEARCH

ENGAGEMENT